# A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

> **NCT03071094** · PHASE1,PHASE2 · TERMINATED · sponsor: **Transgene** · enrollment: 14 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** Pexastimogene Devacirepvec (Pexa Vec)
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03071094
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-27
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-02-03
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459).
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071094, "A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03071094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*